<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006965</article-id><article-id pub-id-type="pmc">PMC11861156</article-id><article-id pub-id-type="doi">10.3390/v17020210</article-id><article-id pub-id-type="publisher-id">viruses-17-00210</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Novel Oronasal Drainage for Long COVID: Proposed Mechanisms&#x02014;Case Report</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lorenz</surname><given-names>Claudia</given-names></name><xref rid="af1-viruses-17-00210" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Frankenberger</surname><given-names>Roland</given-names></name><xref rid="af2-viruses-17-00210" ref-type="aff">2</xref><xref rid="c1-viruses-17-00210" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Takada</surname><given-names>Ayato</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00210"><label>1</label>Department of Operative Dentistry, Sanit&#x000e4;tszentrum Pfreimd, Schlo&#x000df;bergstr. 1, 92536 Pfreimd, Germany; <email>claudia-lorenz@posteo.de</email></aff><aff id="af2-viruses-17-00210"><label>2</label>Department of Operative Dentistry and Endodontics, Dental School, University of Marburg and University Medical Center Giessen and Marburg, 35039 Marburg, Germany</aff><author-notes><corresp id="c1-viruses-17-00210"><label>*</label>Correspondence: <email>frankbg@uni-marburg.de</email>; Tel.: +49-642-158-632-14</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>210</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Long COVID, potentially emerging post COVID-19 infection, involves extreme health challenges. Based on current literature in the field, we propose a novel approach to Long COVID treatment based on epipharyngeal abrasive therapy targeting ostia of the oral and nasal mucosa, having been identified for the first time. The presented case report documents the application of innovative oronasal drainage (OND), a novel treatment integrating physiological, biochemical, and fluid mechanical components simultaneously. OND led to remarkable improvements and even remissions of various symptoms, along with enhanced hand blood circulation. While the case suggests potential efficacy in Long COVID therapy, acknowledging inherent limitations is essential and its impact needs further validation through clinical trials.</p></abstract><kwd-group><kwd>Long COVID</kwd><kwd>oronasal drainage (OND)</kwd><kwd>myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)</kwd><kwd>ostia</kwd><kwd>oral</kwd><kwd>nose</kwd><kwd>case report</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00210"><title>1. Introduction</title><p>The oral and pharyngeal mucosa are fundamental targets of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<xref rid="B1-viruses-17-00210" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-00210" ref-type="bibr">2</xref>]. A recent meta-analysis indicated a 45% risk of persistent symptoms four months post-infection [<xref rid="B3-viruses-17-00210" ref-type="bibr">3</xref>], with a higher incidence among females [<xref rid="B4-viruses-17-00210" ref-type="bibr">4</xref>]. Cumulative reinfections further elevate the risk of Long COVID [<xref rid="B5-viruses-17-00210" ref-type="bibr">5</xref>].</p><p>The prevalence of chronic epipharyngitis in Long COVID reaches 100% [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>]. Applying a cotton laryngeal swab, inserted in 0.5% zinc chloride (ZnCl<sub>2</sub>) solution, to the epipharynx has shown significant improvements in chronic cough [<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>]. Notably, epipharyngeal abrasive therapy (EAT), involving the abrasive removal of mucus with 0.5% ZnCl<sub>2</sub> solution, has received approval for treating acute COVID infections and Long COVID in Japan [<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00210" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-00210" ref-type="bibr">9</xref>], supported by a recent comprehensive study [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>].</p><p>In Germany, no therapies for the treatment of Long COVID are currently approved, besides strong evidence that SARS-CoV-2 can persist [<xref rid="B10-viruses-17-00210" ref-type="bibr">10</xref>,<xref rid="B11-viruses-17-00210" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-00210" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00210" ref-type="bibr">13</xref>,<xref rid="B14-viruses-17-00210" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>]. In this context, we introduce an innovative therapeutic approach&#x02014;the oronasal drainage (OND), invented by Claudia Lorenz&#x02014;targeting the lymphoepithelial tissue of the oral and nasal mucosa (ONM) using 0.5% ZnCl<sub>2</sub> solution. This report marks the first global description and systematic use of the OND method, developed and implemented in Germany. The primary objective of OND is the direct elimination of infected cells at the point of entry. In contrast to EAT, OND abstains from the abrasive removal of mucus. Instead, it employs a spiral excretion technique that follows the natural link of secretion. OND offers significant advantages over EAT, as it minimizes or entirely eliminates bleeding and spares the patient from experiencing pain [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>]. Furthermore, OND targets multiple sites with the objective of more effectively reducing the possible presence of actively replicating virus, consequently leading to a greater alleviation of manifestations [<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>,<xref rid="B16-viruses-17-00210" ref-type="bibr">16</xref>].</p><p>This treatment was administered to a 57-year-old woman experiencing Long COVID and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), involving multiple OND per day over five consecutive days in September 2023 and no evidence of SARS-CoV-2 infection at that time. Remarkably, the outcomes of the OND intervention demonstrated systemic, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, and neuropsychiatric improvements. Additionally, remissions of gynecological and gastrointestinal complaints were observed, accompanied by enhanced palmar blood circulation. Enhancement enabled patient&#x02019;s partial resumption of duties including public appearances.</p></sec><sec id="sec2-viruses-17-00210"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-17-00210"><title>2.1. Safety and Ethics</title><p>The OND method is currently in the experimental phase, prioritizing stringent adherence to safety and ethical standards through meticulous clarification, documentation, and responsible handling.</p><p>Safety measures are implemented, treating removed secretions as potentially infectious. Risk of infection through aerosol-generating procedures is mitigated by employing a HEPA air purifier during OND [<xref rid="B17-viruses-17-00210" ref-type="bibr">17</xref>]. The practitioner wears personal protective equipment, including goggles, FFP2 mask, visor, hooded suit, disposable gloves, and shoe covers. Additionally, the individual undergoing OND wears protective goggles with cotton pads for further protection.</p></sec><sec id="sec2dot2-viruses-17-00210"><title>2.2. Materials</title><p>Essential materials for OND include sterile 15 cm long, straight cotton swabs soaked in 0.5% ZnCl<sub>2</sub> solution and lidocaine pump spray. The 0.5% ZnCl<sub>2</sub> solution, a standard component for EAT in Japan [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>,<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00210" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-00210" ref-type="bibr">9</xref>], was used off-label for a single individual in Germany for OND, ensuring responsible product handling. A case report documented a patient&#x02019;s self-administration of EAT, demonstrating improved renal function and relief from a sore throat, underscoring the low risk in self-treatment [<xref rid="B18-viruses-17-00210" ref-type="bibr">18</xref>]. The OND employs sterile straight cotton swabs, enabling targeting of ostia and crypts and rotation, unlike the EAT that utilizes angled instruments on a flat surface.</p><p>Topical pharyngeal anesthesia, administered using a lidocaine pump spray in a supine position, effectively minimizes the possibility of a gagging reflex during OND [<xref rid="B19-viruses-17-00210" ref-type="bibr">19</xref>].</p></sec><sec id="sec2dot3-viruses-17-00210"><title>2.3. Patient Selection Criteria</title><p>Patient selection involves confirmed SARS-CoV-2 infection through PCR testing and a diagnosis of Long COVID, possibly caused by virus persistence [<xref rid="B10-viruses-17-00210" ref-type="bibr">10</xref>,<xref rid="B11-viruses-17-00210" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-00210" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00210" ref-type="bibr">13</xref>,<xref rid="B14-viruses-17-00210" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>]. Exclusion criteria encompass minors and probands already participating in studies elsewhere, ensuring a targeted focus on the unique aspects of OND in the context of treatment in this population.</p></sec><sec id="sec2dot4-viruses-17-00210"><title>2.4. Overview of OND</title><p>Despite the potential severity of symptoms associated with Long COVID, there are currently only off-label treatments available in Germany [<xref rid="B20-viruses-17-00210" ref-type="bibr">20</xref>]. Introduced for the first time, OND is an evolution of EAT from Japan, involving the abrasive removal of mucus from the epipharynx using a 0.5% ZnCl<sub>2</sub> solution [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>,<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00210" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-00210" ref-type="bibr">9</xref>] OND represents an alternative therapeutic approach for Long COVID, integrating simultaneously physiological, biochemical, and fluid mechanical components to expel exocrine secretions and initiate a healing cycle.</p><sec id="sec2dot4dot1-viruses-17-00210"><title>2.4.1. Site of Action</title><p>OND precisely targets the lymphoepithelial tissue in the ONM, where the epithelium houses angiotensin-converting enzyme 2, facilitating the entry of SARS-CoV-2 into host cells [<xref rid="B2-viruses-17-00210" ref-type="bibr">2</xref>]. Specifically, the focus is on the less-explored and first time identified ostia, partly hidden inside crypts and plicae, of mucosa-associated lymphoid tissue (MALT), including tonsilla lingualis, tonsilla palatina, tonsilla pharyngealis, and tonsilla tubaria [<xref rid="B21-viruses-17-00210" ref-type="bibr">21</xref>,<xref rid="B22-viruses-17-00210" ref-type="bibr">22</xref>] (<xref rid="viruses-17-00210-f001" ref-type="fig">Figure 1</xref>a&#x02013;c). Given the established transmission routes of SARS-CoV-2 through the eye, nose, or mouth [<xref rid="B2-viruses-17-00210" ref-type="bibr">2</xref>,<xref rid="B23-viruses-17-00210" ref-type="bibr">23</xref>,<xref rid="B24-viruses-17-00210" ref-type="bibr">24</xref>], and in consideration of viral persistence on the tongue [<xref rid="B10-viruses-17-00210" ref-type="bibr">10</xref>], adenoids and tonsils [<xref rid="B25-viruses-17-00210" ref-type="bibr">25</xref>], we hypothesize that the entry points primarily coincide with the exit points of the virus [<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>].</p></sec><sec id="sec2dot4dot2-viruses-17-00210"><title>2.4.2. Physiological Component</title><p>Recent research supports the exploration of ostia, especially in the ONM, indicating their sphincter function [<xref rid="B26-viruses-17-00210" ref-type="bibr">26</xref>]. Mechanical stimulation, such as with cotton swabs, exposes ostia within mucosal plicae and crypts.</p></sec><sec id="sec2dot4dot3-viruses-17-00210"><title>2.4.3. Biochemical Component</title><p>Cystic fibrosis transmembrane conductance regulator and SARS-CoV-2 accessory protein ORF3a form the biochemical basis for OND, considering their roles in chloride ions transport [<xref rid="B27-viruses-17-00210" ref-type="bibr">27</xref>] and altered dynamics of chloride channels [<xref rid="B28-viruses-17-00210" ref-type="bibr">28</xref>], respectively.</p><p>The 0.5% ZnCl<sub>2</sub> solution demonstrates antibacterial properties within the oral cavity [<xref rid="B29-viruses-17-00210" ref-type="bibr">29</xref>], and its anti-inflammatory effect in the epipharynx is evidenced by a suppressed expression of TNF-&#x003b1;, IL-6, and decreased number of CD4(+) T cells alongside symptomatic recovery [<xref rid="B8-viruses-17-00210" ref-type="bibr">8</xref>,<xref rid="B30-viruses-17-00210" ref-type="bibr">30</xref>]. We therefore hypothesize that the opening of blocked ostia is facilitated by the chloride ions being present in the ZnCl<sub>2</sub> solution [<xref rid="B28-viruses-17-00210" ref-type="bibr">28</xref>].</p></sec><sec id="sec2dot4dot4-viruses-17-00210"><title>2.4.4. Fluid Mechanical Component</title><p>OND is proposed to rely on a mechanism involving clockwise rotation, possibly linked to cell differentiation [<xref rid="B31-viruses-17-00210" ref-type="bibr">31</xref>] and the structure of the SARS-CoV-2 virus [<xref rid="B28-viruses-17-00210" ref-type="bibr">28</xref>,<xref rid="B32-viruses-17-00210" ref-type="bibr">32</xref>]. This technique, executed in a spiral, clockwise manner from the patient&#x02019;s perspective using extended cotton swabs, facilitates the absorption of secretions due to mucus adhesion [<xref rid="B9-viruses-17-00210" ref-type="bibr">9</xref>]. The absorbed secretion onto the cotton swab forms a long thread, resembling a spindle [<xref rid="B33-viruses-17-00210" ref-type="bibr">33</xref>].</p></sec><sec id="sec2dot4dot5-viruses-17-00210"><title>2.4.5. Secretions</title><p>OND aims to expel inflammatory fluids, potentially containing SARS-CoV-2 parts [<xref rid="B16-viruses-17-00210" ref-type="bibr">16</xref>], through tears, nasal secretions, and saliva along the most direct route. Fluid management involves wiping tears, gently sniffing nasal secretions into a cellulose cloth, and expectorating saliva into a designated vessel. Large respiratory droplets carrying SARS-CoV-2 virus deposit due to gravitational force [<xref rid="B34-viruses-17-00210" ref-type="bibr">34</xref>]. Utilizing a pillow to enhance the natural flow of these fluids, the individual consistently assumes a slightly forward-leaning position, typically seated with the head bent forward.</p></sec><sec id="sec2dot4dot6-viruses-17-00210"><title>2.4.6. Side Effects</title><p>Immune responses induced by OND, resembling a flu-like experience, parallel the regression of an acute viral infection [<xref rid="B35-viruses-17-00210" ref-type="bibr">35</xref>]. Thus, essential parameters, including oxygen saturation, heart rate, and blood pressure, are assessed before and after each treatment day. Due to the possibility of aspirating potentially infectious saliva secretions during the spitting process [<xref rid="B2-viruses-17-00210" ref-type="bibr">2</xref>], there is a risk of herpes simplex virus 1 (HSV-1) reactivation [<xref rid="B36-viruses-17-00210" ref-type="bibr">36</xref>].</p></sec><sec id="sec2dot4dot7-viruses-17-00210"><title>2.4.7. Treatment Cycle</title><p>Treatment sessions, lasting 15 to 20 min and interspersed with breaks for rest and recovery, serve as a prerequisite for the inherent self-healing process [<xref rid="B37-viruses-17-00210" ref-type="bibr">37</xref>]. Regular hydration is provided to counteract fluid loss, and the drainage frequency is adapted to the patient&#x02019;s exercise capacity (<xref rid="viruses-17-00210-f0A1" ref-type="fig">Figure A1</xref>).</p><p>Altogether, OND presents an innovative therapeutic strategy for Long COVID with potential impact that seamlessly blends physiological, biochemical, and fluid mechanical elements. The main goal of OND is to target the root cause of viral persistence at the entry points in the ONM, potentially resulting in significant systematic symptom alleviation for individuals suffering from Long COVID.</p></sec></sec></sec><sec id="sec3-viruses-17-00210"><title>3. Case Report</title><sec id="sec3dot1-viruses-17-00210"><title>3.1. Anamnesis</title><p>A 57-year-old female, four-time BioNTech vaccine recipient, suffered SARS-CoV-2 in September 2022, confirmed through polymerase chain reaction (Ct = 29.0). Pre-existing conditions included arterial hypertension, hypothyroidism, and type-2 diabetes, managed with Siofor, L-thyroxine, and irbesartan. Post-infection, the patient experienced severe post-exertional malaise (PEM) and was officially diagnosed with Long COVID, fibromyalgia, restless legs syndrome, and ME/CFS. Medications included rupatadine, monteluclast, prednisolone, nattokinase (100 mg, nine months), and nicotine patches (3.5&#x02013;7 mg, four months). PEM, coupled with cognitive impairment and dyspnea resulted in inability to perform patient&#x02019;s managerial social work role.</p></sec><sec id="sec3dot2-viruses-17-00210"><title>3.2. Physical Examination</title><p>The extraoral examination identified a pale, slightly yellow, adipose face. The intraoral assessment revealed an inconspicuous dentition with conservative and prosthetic restorations. According to the patient, a tongue scraper had been used every day for months; the tongue appeared enlarged, pale, and with little coating. Further, the patient reported recurrent loss of two 10-year-old dental restorations since the SARS-CoV-2 infection, requiring repeated conservative treatment.</p><p>Diagnostic imaging included intraoral and extraoral photos, along with hand images. Intraorally, the salivary secretion appeared elongated and thread-like (<xref rid="viruses-17-00210-f002" ref-type="fig">Figure 2</xref>a). Notably, the patient experienced significant fatigue even before the intervention while capturing the photographs.</p></sec><sec id="sec3dot3-viruses-17-00210"><title>3.3. Interventions</title><p>The intervention involved OND administered for five consecutive days on a dental chair, with each session comprising three to four therapy units. Due to the potential risk of vomiting resulting from a pronounced gag reflex, the patient underwent a fasting period. Initially, OND was carried out on the oral mucosa, specifically targeting the upper oral ostia next to the tonsilla palatina of the individual due to an enlarged tongue (<xref rid="viruses-17-00210-f002" ref-type="fig">Figure 2</xref>b). Subsequently, after a period of nutritional intake and regeneration, OND of the nasal mucosa was performed on both nostrils in the following step (<xref rid="viruses-17-00210-f002" ref-type="fig">Figure 2</xref>c).</p></sec><sec id="sec3dot4-viruses-17-00210"><title>3.4. Evaluation</title><p>Symptoms were systematically assessed before, during, and one month after the OND intervention, utilizing a comprehensive list of Long COVID associated symptoms and functional scales ranging from 0 (no symptoms) to 8 (most severe symptoms) [<xref rid="B38-viruses-17-00210" ref-type="bibr">38</xref>]. Throughout the OND sessions, we monitored vital signs, observed changes in the HEPA device display, and captured images of the hands. Post-OND, the patient self-monitored vital signs and daily symptoms in constant communication. Additionally, a histological examination through enzyme-linked immunosorbent assay, aimed at detecting the SARS-CoV-2 spike protein (S protein) in nasal and oral secretions from the second day of treatment, was conducted based on the patient&#x02019;s explicit request and at their own expense. Statistical analyses included biserial correlation and the Cochran Q test.</p></sec><sec id="sec3dot5-viruses-17-00210"><title>3.5. Results</title><p>Patient&#x02019;s resting heart rate was 81.0 three days before the start of OND (<italic toggle="yes">n</italic> = 1), averaging 75.6 &#x000b1; 4.7 during therapy (<italic toggle="yes">n</italic> = 5), and averaging 78.2 &#x000b1; 3.1 at the one-month follow-up (<italic toggle="yes">n</italic> = 30). Throughout OND therapy, blood pressure ranged from an average of 129.2 &#x000b1; 5.6 to 75.0 &#x000b1; 2.5 (<italic toggle="yes">n</italic> = 5), and at the one-month follow-up, it ranged from an average of 123 7 &#x000b1; 7.2 to 77.0 &#x000b1; 5.8 (<italic toggle="yes">n</italic> = 30). Oxygen saturation averaged 93.8% &#x000b1; 3.0 during OND (<italic toggle="yes">n</italic> = 5), with the lowest saturation recorded at 90% on the second day.</p><p>The HEPA filter was regularly very low (5&#x02013;6/100), reaching higher values when sneezing related to OND (13/100) [<xref rid="B17-viruses-17-00210" ref-type="bibr">17</xref>]. The texture of the secretion collected from both nasal and oral mucosa manifested as a stringy, transparent mucus measuring several centimeters in length (<xref rid="viruses-17-00210-f003" ref-type="fig">Figure 3</xref>a&#x02013;c, white triangle). By the fourth day of OND, minimal quantities of green nasal secretion were expelled through snorting (<xref rid="viruses-17-00210-f003" ref-type="fig">Figure 3</xref>b, black triangle). With an analytical sensitivity of unbound S protein detection of 4.5 pg/mL, no S proteins were detected in the nasal-mouth secretions examined (<xref rid="viruses-17-00210-f003" ref-type="fig">Figure 3</xref>c).</p><p>Upon the initiation of OND, the individual encountered a flu-like experience such as watery eyes, sneezing, sniffling, coughing, a fleeting sensation of fever, back pain, and momentary exhaustion. These indications peaked on the second day of treatment and subsided on the tenth day post-treatment initiation (<xref rid="viruses-17-00210-f003" ref-type="fig">Figure 3</xref>b, black arrow). In addition, the patient reported a metallic taste and developed HSV-1 on the lower lip on the fourth day of OND (<xref rid="viruses-17-00210-f002" ref-type="fig">Figure 2</xref>c, black arrow), with both symptoms resolving by the eighth day.</p><p>Symptom improvements exhibited a positive correlation with OND, indicating moderate effects on the tenth day post-treatment initiation (Cohen&#x02019;s d = 0.44, <xref rid="viruses-17-00210-f004" ref-type="fig">Figure 4</xref>a, black data). These effects persisted and remained stable one month following the conclusion of the treatment (<xref rid="viruses-17-00210-f004" ref-type="fig">Figure 4</xref>b).</p><p>OND treatment resulted in significant improvements in PEM (<xref rid="viruses-17-00210-f004" ref-type="fig">Figure 4</xref>a, blue data), dyspnea (<xref rid="viruses-17-00210-f004" ref-type="fig">Figure 4</xref>c), respiratory issues, abdominal pain, nausea, sensorimotor complaints and food intolerances (<xref rid="viruses-17-00210-t0A1" ref-type="table">Table A1</xref>) [<xref rid="B38-viruses-17-00210" ref-type="bibr">38</xref>]. Remissions were observed in reproductive organs, allergies and diarrhea (<xref rid="viruses-17-00210-t0A1" ref-type="table">Table A1</xref>, green data). Improvements were accompanied by visibly enhanced blood circulation in the hands (<xref rid="viruses-17-00210-f005" ref-type="fig">Figure 5</xref>a) as well as slight enhanced blood circulation in patient&#x02019;s tongue tip (<xref rid="viruses-17-00210-f005" ref-type="fig">Figure 5</xref>b). The absence of PEM during OND and the sustained improvement in symptoms enabled the individual to resume volunteer duties including public appearances.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-00210"><title>4. Discussion</title><sec id="sec4dot1-viruses-17-00210"><title>4.1. In General</title><p>The innovative OND resulted in moderate symptom improvements across multiple systems (systemic, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, and neuropsychiatric domains) in an individual affected by Long COVID. Furthermore, resting heart rate slightly improved. Blood pressure also had a tendency to normalize.</p><p>The case report showcases notable strengths, demonstrating substantial alleviation of Long COVID manifestations in a single patient. Furthermore, the remission of gynecological and gastrointestinal complaints, along with marked relief in food intolerance, underscores the positive impact of this novel treatment approach for Long COVID. Notably, the absence of PEM during OND is noteworthy, especially considering that existing literature provides only broad self-management strategies for ME/CFS [<xref rid="B39-viruses-17-00210" ref-type="bibr">39</xref>]. Among the most prevalent Long COVID symptoms, fatigue showed a slight improvement, while dyspnea drastically improved during OND [<xref rid="B40-viruses-17-00210" ref-type="bibr">40</xref>]. Additionally, OND emerged as an effective, cost-efficient intervention with a relatively brief treatment duration.</p><p>This case report is subject to certain limitations. The patient could not assess oxygen saturation afterward due to a lack of equipment. Notably, the temporary marginal decrease in oxygen saturation during OND contrasts sharply with the marked improvement in dyspnea observed during and post-therapy [<xref rid="B40-viruses-17-00210" ref-type="bibr">40</xref>]. Enhanced blood circulation in hands and tongue, indicative of systemic improvements, was not conducted for ethical reasons due to limits as a healing attempt. The use of a tongue scraper by the patient to address a coated tongue, associated with SARS-CoV-2 virus persistence, introduces a potential confounder [<xref rid="B10-viruses-17-00210" ref-type="bibr">10</xref>]; however, its impact seems marginal considering the patient&#x02019;s long-term use.</p><p>Moreover, there is currently no identified evidence indicating dental restoration loss in this population based on our knowledge, reflecting limited data. The necessity for a rigorous histological examination of nasal-mouth secretions, along with broader, randomized studies, underscores the preliminary nature of the findings. The cost-effectiveness of OND makes studies akin to this case report relatively straightforward to conduct. While the lack of blinding raises concerns about potential psychosomatic influences [<xref rid="B41-viruses-17-00210" ref-type="bibr">41</xref>], a three-month post-intervention follow-up showed no observed symptom-related relapses, supported by age-appropriate normal findings on cranial MRI.</p></sec><sec id="sec4dot2-viruses-17-00210"><title>4.2. Laboratory Findings&#x02014;SARS-CoV-2 S Protein</title><p>During OND, a slight increase in aerosols indicated non-specific contamination, potentially involving SARS-CoV-2 particles [<xref rid="B17-viruses-17-00210" ref-type="bibr">17</xref>]. Existing literature supports the persistence of S proteins from SARS-CoV-2 [<xref rid="B11-viruses-17-00210" ref-type="bibr">11</xref>]. However, the absence of histologically detectable S protein in nasal-mouth secretions may be attributed to various factors. Firstly, targeting exclusively unbound S proteins might have led to insufficient measurement sensitivity. Secondly, a histological examination for Nucleocapsid protein [<xref rid="B11-viruses-17-00210" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-00210" ref-type="bibr">12</xref>], Envelope protein, or RNA [<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>] was not carried out due to the absence of precise determination methods. Thirdly, OND intervention twelve months post-acute infection might have contributed, considering the decreasing receptor binding of S protein over the disease course [<xref rid="B12-viruses-17-00210" ref-type="bibr">12</xref>]. Additionally, the prolonged use of nattokinase, a time-dependent protease inhibitor, and nicotine patches four months prior could influence S protein inhibition and receptor binding, respectively [<xref rid="B42-viruses-17-00210" ref-type="bibr">42</xref>,<xref rid="B43-viruses-17-00210" ref-type="bibr">43</xref>].</p><p>Another report demonstrated SARS-CoV-2 RNA persistence in the epipharyngeal mucosa four months post-infection, eliminated with EAT [<xref rid="B9-viruses-17-00210" ref-type="bibr">9</xref>]. However, the higher degradation rate of viral RNA compared to proteins reduces RNA detection likelihood after twelve months in this case [<xref rid="B11-viruses-17-00210" ref-type="bibr">11</xref>]. Further diagnostic analysis is imperative, especially focusing on the Nucleocapsid protein, which constitutes the innermost component of SARS-CoV-2 [<xref rid="B44-viruses-17-00210" ref-type="bibr">44</xref>].</p></sec><sec id="sec4dot3-viruses-17-00210"><title>4.3. Side Effects</title><p>Side effects, interpreted as subacute infection signs, highlight the need for careful monitoring during OND [<xref rid="B35-viruses-17-00210" ref-type="bibr">35</xref>]. Alterations in taste and the reactivation of HSV-1, recognized self-limiting and manageable symptoms following a SARS-CoV-2 infection [<xref rid="B36-viruses-17-00210" ref-type="bibr">36</xref>], occurred during OND, and strengthen suspicion of infected secretions.</p><p>The green coloration in nasal secretion after four days of OND may stem from pre-existing bacterial persistence [<xref rid="B45-viruses-17-00210" ref-type="bibr">45</xref>]. The appropriateness of antibiotics remains debatable, given the very small quantity and patient&#x02019;s relative well-being despite strenuous treatment. Regarding these well-tolerated manifestations as transient side effects associated with OND, we found no urgency for further intervention.</p></sec><sec id="sec4dot4-viruses-17-00210"><title>4.4. Proposed Mechanisms</title><p>SARS-CoV-2 predominantly enters through the nasopharynx [<xref rid="B46-viruses-17-00210" ref-type="bibr">46</xref>]. Post SARS-CoV-2 infection, genetic changes in monocytes [<xref rid="B47-viruses-17-00210" ref-type="bibr">47</xref>], infection of foam cells [<xref rid="B48-viruses-17-00210" ref-type="bibr">48</xref>] and macrophages [<xref rid="B47-viruses-17-00210" ref-type="bibr">47</xref>] suggest a potential role of nasal-mouth secretion in the context of the MALT immune system [<xref rid="B35-viruses-17-00210" ref-type="bibr">35</xref>]. Recognizing viral persistence [<xref rid="B10-viruses-17-00210" ref-type="bibr">10</xref>,<xref rid="B11-viruses-17-00210" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-00210" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00210" ref-type="bibr">13</xref>,<xref rid="B14-viruses-17-00210" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>], the ostia in the ONM emerge as primary sites for SARS-CoV-2 persistence. Employing a novel EAT approach [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>,<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00210" ref-type="bibr">8</xref>] that demonstrates mRNA removal [<xref rid="B9-viruses-17-00210" ref-type="bibr">9</xref>], OND holds promise as an effective treatment for virus elimination. The hypothesized actions encompass the opening of ostia, equalization of chloride ion concentration gradients using a ZnCl<sub>2</sub> solution with a specific emphasis on the ORF3a protein of SARS-CoV-2 [<xref rid="B28-viruses-17-00210" ref-type="bibr">28</xref>,<xref rid="B44-viruses-17-00210" ref-type="bibr">44</xref>]. The high unbinding force of angiotensin-converting enzyme 2 may explain the long secretion thread during OND [<xref rid="B49-viruses-17-00210" ref-type="bibr">49</xref>], potentially involving a chaining of infected cells as the underlying mechanism.</p></sec><sec id="sec4dot5-viruses-17-00210"><title>4.5. Comparison to EAT</title><p>Enhancements in both fatigue and headache are observed in EAT treatment [<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>], emphasizing that OND innovatively expands upon EAT with novel techniques and extended therapeutic applications. In contrast to EAT, OND avoids injuries and bleeding during the treatment process, thereby preventing pain and infection risks, and enhancing patient comfort [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>]. Furthermore, a clinical study investigating oral bloody abrasion in the context of EAT, which resulted in an elevated heart rate in patients with ME/CFS, stands in contrast to the presented case [<xref rid="B30-viruses-17-00210" ref-type="bibr">30</xref>]. Here, the patient with Long COVID and ME/CFS exhibited a slight improvement in heart rate. Moreover, OND&#x02019;s comprehensive influence on the patient&#x02019;s overall health stands in contrast to EAT&#x02019;s specific focus on addressing chronic cough [<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>]. Consequently, OND is generally considered superior to EAT.</p></sec><sec id="sec4dot6-viruses-17-00210"><title>4.6. Future Research</title><p>In subsequent studies, to address the initial exacerbation resembling the onset of a flu-like infection, peaking after two days, OND should be monitored via clinical thermometer and temporarily suspended for one day after a two-day treatment duration. This pause is intended to facilitate the regeneration process.</p><p>The frequency of therapy sessions should vary based on viral load, disease duration, and severity, with 20&#x02013;40 treatments within 24&#x02013;36 weeks being common for EAT and potentially applicable for OND [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>,<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>,<xref rid="B16-viruses-17-00210" ref-type="bibr">16</xref>,<xref rid="B50-viruses-17-00210" ref-type="bibr">50</xref>]. While the current case report does not include diagnostic assessments of viral load or disease duration due to ethical constraints, these aspects should be systematically investigated in future clinical studies. Moreover, given the minimal risk of PEM, the assessment of hand grip strength could serve as a straightforward diagnostic tool for evaluating systemic alterations [<xref rid="B51-viruses-17-00210" ref-type="bibr">51</xref>].</p></sec><sec id="sec4dot7-viruses-17-00210"><title>4.7. Lymphatic Tissue Involvement in Long COVID: A Hypothesized Mechanism and Potential Therapeutic Approach</title><p>Following a SARS-CoV-2 infection, inadequate viral elimination may be the primary factor contributing to the onset of the secondary condition known as Long COVID [<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>,<xref rid="B52-viruses-17-00210" ref-type="bibr">52</xref>]. Our hypothesis suggests Long COVID as a disorder related to the lymphatic tissue, taking into consideration viral entry points [<xref rid="B46-viruses-17-00210" ref-type="bibr">46</xref>], replication of SARS-CoV-2 across ocular tissue, nasopharynx and oropharynx [<xref rid="B14-viruses-17-00210" ref-type="bibr">14</xref>], as well as viral persistence in the pharyngeal lymphoid tissue [<xref rid="B25-viruses-17-00210" ref-type="bibr">25</xref>] and the enlargement of cervical lymph nodes [<xref rid="B53-viruses-17-00210" ref-type="bibr">53</xref>]. Furthermore, our hypothesis considers factors such as immune response attack on spleen and lymphoid nodes [<xref rid="B54-viruses-17-00210" ref-type="bibr">54</xref>], perithymic lymphadenopathy linked to severe disease and death [<xref rid="B55-viruses-17-00210" ref-type="bibr">55</xref>], and the removal of previously infected MALT cells [<xref rid="B9-viruses-17-00210" ref-type="bibr">9</xref>]. Decontamination and reactivation of all infected ostia in the mouth, nose, and eyes could play a pivotal role in addressing Long COVID symptoms possibly associated with these openings [<xref rid="B14-viruses-17-00210" ref-type="bibr">14</xref>,<xref rid="B21-viruses-17-00210" ref-type="bibr">21</xref>,<xref rid="B23-viruses-17-00210" ref-type="bibr">23</xref>,<xref rid="B24-viruses-17-00210" ref-type="bibr">24</xref>]. Consequently, targeting ostia in the ONM, OND emerges as a potential key component in Long COVID treatment. However, further research is crucial to validate these hypotheses, considering factors such as SARS-CoV-2 viral load and the involvement of MALT and ostia in viral diseases [<xref rid="B15-viruses-17-00210" ref-type="bibr">15</xref>,<xref rid="B16-viruses-17-00210" ref-type="bibr">16</xref>,<xref rid="B50-viruses-17-00210" ref-type="bibr">50</xref>].</p></sec></sec><sec id="sec5-viruses-17-00210"><title>5. Conclusions</title><p>In conclusion, OND introduces a novel and carefully considered therapeutic approach for Long COVID. By integrating physiological, biochemical, and fluid mechanical components, OND aims to address specific aspects of viral persistence within the ONM. Despite experimental stages and temporary side effects, OND emphasizes safety commitment and presents a unique avenue for investigating potential solutions to the lingering effects of Long COVID. As we cautiously navigate the landscape of post-acute sequelae, OND offers a noteworthy contribution to the ongoing discourse on effective treatments for individuals experiencing prolonged complaints after SARS-CoV-2 infection. The case report suggests that OND may lead to rapid symptom alleviation and functional recovery. However, further research and clinical trials will be essential for robust conclusions to determine the true impact and feasibility of OND in Long COVID management.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are immensely grateful to the patient. We would also like to thank Daniela Keller for the statistical analysis.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, C.L.; methodology, C.L.; validation, C.L. and R.F.; formal analysis, C.L.; investigation, C.L. and R.F.; data curation, C.L.; writing&#x02014;original draft preparation, C.L.; writing&#x02014;review and editing, R.F.; supervision, R.F.; project administration, C.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Written informed consent was obtained from the patient. Ethical review and approval were waived for this study due to the healing attempt adhered to ethical principles for curative interventions. Administered to a single patient experiencing unbearable suffering with no available alternatives, the treatment addressed underlying Long COVID conditions lacking recognized treatments in Germany. The patient received comprehensive information, and the process was meticulously documented. The intervention utilized EAT, approved in Japan for acute SARS-CoV-2 infection and Long COVID [<xref rid="B6-viruses-17-00210" ref-type="bibr">6</xref>,<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00210" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-00210" ref-type="bibr">9</xref>]. Clinical evidence supports its efficacy, particularly in chronic cough [<xref rid="B7-viruses-17-00210" ref-type="bibr">7</xref>]. Expanding the technique and treatment areas were based on the author&#x02019;s self-experimentation and thorough research [<xref rid="B56-viruses-17-00210" ref-type="bibr">56</xref>]. Therefore, requirements for the intervention were fulfilled without needing ethics committee approval.</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent was obtained from all the patients involved in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><app-group><app id="app1-viruses-17-00210"><title>Appendix A</title><fig position="anchor" id="viruses-17-00210-f0A1"><label>Figure A1</label><caption><p>Proposed mechanism of Oronasal Drainage (OND) for Long COVID treatment. Cycle chart outlining the hypothesized treatment cycle for OND. The proposed mechanism involves OND sessions lasting less than 20 min, followed by phases of exhaustion, thirst, and initial regeneration. Subsequently, hunger and food intake lead to a brief convalescence, succeeded by extended regeneration and prolonged convalescence.</p></caption><graphic xlink:href="viruses-17-00210-g0A1" position="float"/></fig><table-wrap position="anchor" id="viruses-17-00210-t0A1"><object-id pub-id-type="pii">viruses-17-00210-t0A1_Table A1</object-id><label>Table A1</label><caption><p>Improvements of Long COVID associated symptoms through Oronasal Drainage (OND), before, during and post treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style=" border-top: solid thin; border-top: solid thin; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style=" border-top: solid thin; border-top: solid thin; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style=" border-top: solid thin; border-top: solid thin; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">
</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Symptom Severity</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">OND Treatment</italic>
</th><th align="center" valign="middle" style="border-right:thin solid #F08791" rowspan="1" colspan="1">Before</th><th colspan="2" align="center" valign="middle" style="border-right:thin solid #F08791; background:#F08791" rowspan="1">While OND</th><th colspan="4" align="center" valign="middle" rowspan="1">Follow-Up After OND</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Days</italic>
</th><th align="center" valign="middle" style="border-right: thin solid #F08791" rowspan="1" colspan="1">&#x02212;3</th><th colspan="2" align="center" valign="middle" style="background:#F08791; border-right:thin solid #F08791; background:#F08791" rowspan="1">1&#x02013;5</th><th colspan="2" align="center" valign="middle" rowspan="1">6&#x02013;10</th><th colspan="2" align="center" valign="middle" rowspan="1">10&#x02013;35</th></tr><tr><th align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="center" valign="middle" style="border-right:thin solid #F08791; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">1</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin; border-right:solid thin; background:#F08791; border-right-color:#F08791" rowspan="1">5</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">5</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">25</th></tr><tr><th align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">Category</th><th align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">Symptom</th><th align="center" valign="middle" style="border-right: solid thin; border-right-color: inherit; border-right: solid thin; border-bottom: solid thin; border-bottom: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin; border-right:solid thin; border-right-color:#F08791" rowspan="1" colspan="1">SD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" style="border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">SD</th><th align="center" valign="middle" style="border-bottom-style: solid; border-bottom: solid thin" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">systemic</td><td align="center" valign="middle" rowspan="1" colspan="1">fatigue</td><td align="center" valign="middle" style="background:#FF4000; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">7.00</td><td align="center" valign="middle" style="background:#FF6600" rowspan="1" colspan="1">6.40</td><td align="center" valign="middle" style="border-right:thin solid #F08791; background:#FF6600" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="background:#FF9A00" rowspan="1" colspan="1">5.60</td><td align="center" valign="middle" style="background:#FF9A01" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="background:#FFC000" rowspan="1" colspan="1">5.00</td><td align="center" valign="middle" style="background:#FFC100" rowspan="1" colspan="1">0.89</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PEM</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#59CB34" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="background:#59CC34; border-right:thin solid #F08791" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="background:#72D32C" rowspan="1" colspan="1">1.80</td><td align="center" valign="middle" style="background:#72D32B" rowspan="1" colspan="1">0.83</td><td align="center" valign="middle" style="background:#C1EC14" rowspan="1" colspan="1">3.04</td><td align="center" valign="middle" style="background:#BFEB16" rowspan="1" colspan="1">1.11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">sweats</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#FFB300" rowspan="1" colspan="1">5.20</td><td align="center" valign="middle" style="background:#FFB400; border-right:thin solid #F08791" rowspan="1" colspan="1">1.64</td><td align="center" valign="middle" style="background:#FFD900" rowspan="1" colspan="1">4.60</td><td align="center" valign="middle" style="background:#FFD900" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#F0FA05" rowspan="1" colspan="1">3.77</td><td align="center" valign="middle" style="background:#F1FA09" rowspan="1" colspan="1">1.27</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">temperature issues</td><td align="center" valign="middle" style="background:#FF4000; border-right-color: #F08791; border-bottom: solid thin" rowspan="1" colspan="1">7.00</td><td align="center" valign="middle" style="background:#FF4D00; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">6.80</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#FF4D00; border-right-color:#F08791" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFC000" rowspan="1" colspan="1">5.00</td><td align="center" valign="middle" style="background:#FFC100;border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#F5FB04;border-bottom:solid thin" rowspan="1" colspan="1">3.85</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F5FC02" rowspan="1" colspan="1">1.19</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">pulmonary</td><td align="center" valign="middle" rowspan="1" colspan="1">awakened feeling of not being able to breathe</td><td align="center" valign="middle" style="background:#7FD728; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050; border-right:solid thin; border-right-color: #F08791" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">dry cough</td><td align="center" valign="middle" style="background:#BFEB14; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="background:#7FD728" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="background:#7FD728; border-right:solid thin; border-right-color: #F08791" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="background:#3FC33C" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="background:#3EC43C" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#3FC33C" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="background:#3EC43C" rowspan="1" colspan="1">0.28</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">respiratory issues</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#B2E718" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" style="border-right:solid thin;background:#B2E719" rowspan="1" colspan="1">1.64</td><td align="center" valign="middle" style="background:#66CF30" rowspan="1" colspan="1">1.60</td><td align="center" valign="middle" style="background:#66CF2F" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="background:#3AC23E" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" style="background:#38C33E" rowspan="1" colspan="1">0.63</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">dyspnea</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#66CF30;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">1.60</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#66CF2F;border-right-color: #F08791" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#59CB34" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="background:#59CC34;border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#55CA36;border-bottom:solid thin" rowspan="1" colspan="1">1.35</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#55CB36" rowspan="1" colspan="1">0.49</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">cardiovascular</td><td align="center" valign="middle" rowspan="1" colspan="1">high blood pressure</td><td align="center" valign="middle" style="background:yellow; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" style="background:#26BB44" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" style="background:#26BB44; border-right:solid thin; border-right-color: #F08791" rowspan="1" colspan="1">1.34</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#09B34D" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" style="background:#0AB34D" rowspan="1" colspan="1">0.46</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">palpitations</td><td align="center" valign="middle" style="background:yellow; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" style="background:#59CB34" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="background:#59CC34;border-right:solid thin; border-right-color: #F08791" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#3FC33C" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="background:#3EC43C" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#42C43C" rowspan="1" colspan="1">1.04</td><td align="center" valign="middle" style="background:#3EC43C" rowspan="1" colspan="1">0.20</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">tachycardia</td><td align="center" valign="middle" style="background:#FFC000; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">5.00</td><td align="center" valign="middle" style="background:#F2FB04" rowspan="1" colspan="1">3.80</td><td align="center" valign="middle" style="border-right:solid thin;background:#F2FB06; border-right-color: #F08791" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" style="background:#59CB34" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="background:#59CC34" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#64CF31" rowspan="1" colspan="1">1.58</td><td align="center" valign="middle" style="background:#63D031" rowspan="1" colspan="1">0.58</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">tightness of chest</td><td align="center" valign="middle" style="background:#BFEB14; border-right: solid thin; border-right-color: #F08791;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="background:#8CDB24;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">2.20</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#8CDB24; border-right-color: #F08791" rowspan="1" colspan="1">1.10</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8CDB24" rowspan="1" colspan="1">2.20</td><td align="center" valign="middle" style="background:#8CDB24;border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" style="background:#4EC838;border-bottom:solid thin" rowspan="1" colspan="1">1.23</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#4DC937" rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">gastrointestinal</td><td align="center" valign="middle" rowspan="1" colspan="1">abdominal pain</td><td align="center" valign="middle" style="background:#FF4000; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">7.00</td><td align="center" valign="middle" style="background:#33BF40" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" style="border-right: solid thin; background: #32BF3F; border-right-color: #F08791" rowspan="1" colspan="1">1.30</td><td align="center" valign="middle" style="background:#26BB44" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" style="background:#26BB44" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#33BF40" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" style="background:#32BF3F" rowspan="1" colspan="1">0.90</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">diarrhea</td><td align="center" valign="middle" style="background:#FF4000; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">7.00</td><td align="center" valign="middle" style="background:#4CC738" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" style="border-right: solid thin;background: #4BC837;border-right-color: #F08791" rowspan="1" colspan="1">1.64</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#11B54B" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="background:#11B54B" rowspan="1" colspan="1">0.78</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">nausea</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#FFD900" rowspan="1" colspan="1">4.60</td><td align="center" valign="middle" style="border-right:solid thin;background:#FFD900;border-right-color: #F08791" rowspan="1" colspan="1">3.78</td><td align="center" valign="middle" style="background:#72D32C" rowspan="1" colspan="1">1.80</td><td align="center" valign="middle" style="background:#72D32B" rowspan="1" colspan="1">1.30</td><td align="center" valign="middle" style="background:#5DCC33" rowspan="1" colspan="1">1.46</td><td align="center" valign="middle" style="background:#5CCD33" rowspan="1" colspan="1">0.71</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">vomiting</td><td align="center" valign="middle" style="background:yellow; border-right: solid thin; border-right-color: #F08791;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" style="background:#A5E31C;order-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">2.60</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#A5E31B; border-right-color: #F08791" rowspan="1" colspan="1">3.71</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050;border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050;border-bottom:solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#00B050" rowspan="1" colspan="1">0.00</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">musculoskeletal</td><td align="center" valign="middle" rowspan="1" colspan="1">joint pain</td><td align="center" valign="middle" style="background:#FF4000;border-right: solid thin; border-right-color: inherit; border-right: solid thin" rowspan="1" colspan="1">7.00</td><td align="center" valign="middle" style="background:#66CF30" rowspan="1" colspan="1">1.60</td><td align="center" valign="middle" style="border-right:solid thin;background:#66CF2F; border-right-color: #F08791" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="background:#59CB34" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="background:#59CC34" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#81D828" rowspan="1" colspan="1">2.04</td><td align="center" valign="middle" style="background:#80D827" rowspan="1" colspan="1">0.92</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">muscle aches</td><td align="center" valign="middle" style="background:#FF4000;border-right: solid thin; border-right-color: inherit; border-right: solid thin; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">7.00</td><td align="center" valign="middle" style="background:#59CB34;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#59CC34;border-right-color: #F08791" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#66CF30" rowspan="1" colspan="1">1.60</td><td align="center" valign="middle" style="background:#66CF2F;border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#9FE11E;border-bottom:solid thin" rowspan="1" colspan="1">2.50</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#9FE11E" rowspan="1" colspan="1">1.07</td></tr><tr><td rowspan="10" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">neuro-psychiatric</td><td align="center" valign="middle" rowspan="1" colspan="1">brain fog</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#E5F708" rowspan="1" colspan="1">3.60</td><td align="center" valign="middle" style="border-right:solid thin;background:#E5F705;border-right-color: #F08791" rowspan="1" colspan="1">1.14</td><td align="center" valign="middle" style="background:#FF8D00" rowspan="1" colspan="1">5.80</td><td align="center" valign="middle" style="background:#FF8D02" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="background:#FCFE01" rowspan="1" colspan="1">3.96</td><td align="center" valign="middle" style="background:#FCFF00" rowspan="1" colspan="1">1.18</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">change of smell and taste</td><td align="center" valign="middle" style="background:yellow; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" style="background:#FFA600" rowspan="1" colspan="1">5.40</td><td align="center" valign="middle" style="border-right:solid thin;background:#FFA602;border-right-color: #F08791" rowspan="1" colspan="1">1.14</td><td align="center" valign="middle" style="background:#B2E718" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" style="background:#B2E719" rowspan="1" colspan="1">1.10</td><td align="center" valign="middle" style="background:#50C937" rowspan="1" colspan="1">1.27</td><td align="center" valign="middle" style="background:#50CA36" rowspan="1" colspan="1">0.72</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">dizziness</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#FF0D00" rowspan="1" colspan="1">7.80</td><td align="center" valign="middle" style="border-right:solid thin;background:#FF0A01;border-right-color: #F08791" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="background:#FF5A00" rowspan="1" colspan="1">6.60</td><td align="center" valign="middle" style="background:#FF5A00" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="background:#FFF600" rowspan="1" colspan="1">4.15</td><td align="center" valign="middle" style="background:#FFF602" rowspan="1" colspan="1">0.37</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">headache</td><td align="center" valign="middle" style="background:#FF8000; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">6.00</td><td align="center" valign="middle" style="background:#FFF300" rowspan="1" colspan="1">4.20</td><td align="center" valign="middle" style="border-right:solid thin;background:#FFF301;border-right-color: #F08791" rowspan="1" colspan="1">1.10</td><td align="center" valign="middle" style="background:#D8F30C" rowspan="1" colspan="1">3.40</td><td align="center" valign="middle" style="background:#D9F30C" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#9FE11E" rowspan="1" colspan="1">2.50</td><td align="center" valign="middle" style="background:#9FE11E" rowspan="1" colspan="1">0.91</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">insomnia</td><td align="center" valign="middle" style="background:#BFEB14; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="background:#B2E718" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" style="border-right:solid thin;background:#B2E719;border-right-color: #F08791" rowspan="1" colspan="1">1.48</td><td align="center" valign="middle" style="background:#66CF30" rowspan="1" colspan="1">1.60</td><td align="center" valign="middle" style="background:#66CF2F" rowspan="1" colspan="1">1.34</td><td align="center" valign="middle" style="background:#9CE01F" rowspan="1" colspan="1">2.46</td><td align="center" valign="middle" style="background:#9FE11E" rowspan="1" colspan="1">1.42</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">neuralgia</td><td align="center" valign="middle" style="background:#7FD728; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="background:#26BB44" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" style="border-right:solid thin;background:#26BB44;border-right-color: #F08791" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">other sleep issues</td><td align="center" valign="middle" style="background:#FFC000; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">5.00</td><td align="center" valign="middle" style="background:#B2E718" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" style="border-right:solid thin;background:#B2E719;border-right-color: #F08791" rowspan="1" colspan="1">2.77</td><td align="center" valign="middle" style="background:#66CF30" rowspan="1" colspan="1">1.60</td><td align="center" valign="middle" style="background:#66CF2F" rowspan="1" colspan="1">1.95</td><td align="center" valign="middle" style="background:#6ED22E" rowspan="1" colspan="1">1.73</td><td align="center" valign="middle" style="background:#6ED22E" rowspan="1" colspan="1">0.83</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">restless legs</td><td align="center" valign="middle" style="background:#FFC000; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">5.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-right:solid thin;background:#00B050;border-right-color: #F08791" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#26BB44" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" style="background:#26BB44" rowspan="1" colspan="1">1.34</td><td align="center" valign="middle" style="background:#33BF40" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" style="background:#32BF3F" rowspan="1" colspan="1">0.80</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">sensorimotor issues</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#BFEB14" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="border-right:solid thin;background:#BFEB16;border-right-color: #F08791" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#99DF20" rowspan="1" colspan="1">2.40</td><td align="center" valign="middle" style="background:#99DF20" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#42C43C" rowspan="1" colspan="1">1.04</td><td align="center" valign="middle" style="background:#42C53C" rowspan="1" colspan="1">0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">sleep apnea</td><td align="center" valign="middle" style="background:#7FD728; border-right: solid thin; border-right-color: #F08791; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="background:#00B050;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#00B050;border-right-color: #F08791" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050;border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050;border-bottom:solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#00B050" rowspan="1" colspan="1">0.00</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">immunologic</td><td align="center" valign="middle" rowspan="1" colspan="1">food intolerances</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#FFA600" rowspan="1" colspan="1">5.40</td><td align="center" valign="middle" style="border-right:solid thin;background:#FFA602;border-right-color: #F08791" rowspan="1" colspan="1">1.67</td><td align="center" valign="middle" style="background:#BFEB14" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="background:#BFEB16" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="background:#6ED22E" rowspan="1" colspan="1">1.73</td><td align="center" valign="middle" style="background:#6ED22E" rowspan="1" colspan="1">0.72</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">new allergies</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#00B050; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#00B050;border-right-color: #F08791" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050; border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#07B24E; border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#0AB34D" rowspan="1" colspan="1">0.43</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">endocrine,<break/>reproductive</td><td align="center" valign="middle" rowspan="1" colspan="1">bladder control issues</td><td align="center" valign="middle" style="background:red; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">8.00</td><td align="center" valign="middle" style="background:#8CDB24" rowspan="1" colspan="1">2.20</td><td align="center" valign="middle" style="border-right:solid thin;background:#8CDB24;border-right-color: #F08791" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="background:#BFEB14" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="background:#BFEB16" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#E4F609" rowspan="1" colspan="1">3.58</td><td align="center" valign="middle" style="background:#E4F608" rowspan="1" colspan="1">0.50</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">reproductive organs</td><td align="center" valign="middle" style="background:yellow; border-right: solid thin; border-right-color: #F08791;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" style="background:#72D32C;border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">1.80</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#72D32B;border-right-color: #F08791" rowspan="1" colspan="1">2.49</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050;border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050;border-bottom:solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#00B050" rowspan="1" colspan="1">0.00</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" colspan="1">head, ear, eye, nose, throat</td><td align="center" valign="middle" rowspan="1" colspan="1">hearing issues</td><td align="center" valign="middle" style="background:#BFEB14; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="background:#B2E718" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" style="border-right:solid thin;background:#B2E719;border-right-color: #F08791" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="background:#4CC738" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" style="background:#4BC837" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="background:#3FC33C" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="background:#3EC43C" rowspan="1" colspan="1">0.00</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">runny nose</td><td align="center" valign="middle" style="background:yellow; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" style="background:#7FD728" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="border-right:solid thin;background:#7FD728;border-right-color: #F08791" rowspan="1" colspan="1">1.22</td><td align="center" valign="middle" style="background:#4CC738" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" style="background:#4BC837" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="background:#31BF41" rowspan="1" colspan="1">0.77</td><td align="center" valign="middle" style="background:#2FBF41" rowspan="1" colspan="1">0.82</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">sore throat</td><td align="center" valign="middle" style="background:yellow; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">4.00</td><td align="center" valign="middle" style="background:#7FD728" rowspan="1" colspan="1">2.20</td><td align="center" valign="middle" style="border-right:solid thin;background:#7FD728;border-right-color: #F08791" rowspan="1" colspan="1">2.05</td><td align="center" valign="middle" style="background:#4CC738" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="background:#4BC837" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#31BF41" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" style="background:#2FBF41" rowspan="1" colspan="1">0.40</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">tinnitus</td><td align="center" valign="middle" style="background:#7FD728; border-right: solid thin; border-right-color: #F08791" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="background:#19B748" rowspan="1" colspan="1">0.40</td><td align="center" valign="middle" style="border-right:solid thin;background:#1AB747;border-right-color: #F08791" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#00B050" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="background:#09B34D" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" style="background:#0AB34D" rowspan="1" colspan="1">0.46</td></tr><tr><td align="center" valign="middle" style="border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">vision symptoms</td><td align="center" valign="middle" style="background:#FFC000; border-right: solid thin; border-right-color: #F08791; border-bottom: solid thin; border-bottom: solid thin" rowspan="1" colspan="1">5.00</td><td align="center" valign="middle" style="background:#FFB300; border-bottom: solid thin" rowspan="1" colspan="1">5.20</td><td align="center" valign="middle" style="border-bottom:solid thin;border-right:solid thin;background:#FFB400;border-right-color: #F08791" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#4CC738" rowspan="1" colspan="1">1.20</td><td align="center" valign="middle" style="background:#4BC837; border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="background:#81D828; border-bottom:solid thin" rowspan="1" colspan="1">2.04</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#80D827" rowspan="1" colspan="1">0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dental issues</td><td align="center" valign="middle" style="background:#BFEB14; border-right: thin solid #F08791; border-bottom:solid thin" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="background:#0CB34C;border-bottom:solid thin" rowspan="1" colspan="1">0.20</td><td align="center" valign="middle" style="border-right:thin solid #F08791; background:#0AB34B;border-bottom:solid thin" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="background:#26BB44; border-bottom:solid thin" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" style="background:#26BB44; border-bottom-style: solid; border-bottom-color: inherit; border-bottom: solid thin" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="background:#2EBE42; border-bottom:solid thin" rowspan="1" colspan="1">0.73</td><td align="center" valign="middle" style="background:#2DBE41; border-bottom:solid thin" rowspan="1" colspan="1">0.60</td></tr></tbody></table><table-wrap-foot><fn><p>The traffic lights represent the severity of Long COVID symptoms, rated on a scale from 0 (no symptoms = green) to 8 (most severe symptoms = red), observed in an individual who underwent OND. Symptom progression was tracked three days before, during the five-day treatment, and 30 days post-treatment. Enhancements between 0 and 1 point were omitted for improved readability. PEM = post-exertional malaise. SD = standard deviation.</p></fn></table-wrap-foot></table-wrap></app></app-group><ref-list><title>References</title><ref id="B1-viruses-17-00210"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ivanova</surname><given-names>N.</given-names></name>
<name><surname>Sotirova</surname><given-names>Y.</given-names></name>
<name><surname>Gavrailov</surname><given-names>G.</given-names></name>
<name><surname>Nikolova</surname><given-names>K.</given-names></name>
<name><surname>Andonova</surname><given-names>V.</given-names></name>
</person-group><article-title>Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>530</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14030530</pub-id><pub-id pub-id-type="pmid">35335905</pub-id>
</element-citation></ref><ref id="B2-viruses-17-00210"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bellocchio</surname><given-names>L.</given-names></name>
<name><surname>Dipalma</surname><given-names>G.</given-names></name>
<name><surname>Inchingolo</surname><given-names>A.M.</given-names></name>
<name><surname>Inchingolo</surname><given-names>A.D.</given-names></name>
<name><surname>Ferrante</surname><given-names>L.</given-names></name>
<name><surname>Del Vecchio</surname><given-names>G.</given-names></name>
<name><surname>Malcangi</surname><given-names>G.</given-names></name>
<name><surname>Palermo</surname><given-names>A.</given-names></name>
<name><surname>Qendro</surname><given-names>A.</given-names></name>
<name><surname>Inchingolo</surname><given-names>F.</given-names></name>
</person-group><article-title>COVID-19 on Oral Health: A New Bilateral Connection for the Pandemic</article-title><source>Biomedicines</source><year>2023</year><volume>12</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines12010060</pub-id><pub-id pub-id-type="pmid">38255167</pub-id>
</element-citation></ref><ref id="B3-viruses-17-00210"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Mahoney</surname><given-names>L.L.</given-names></name>
<name><surname>Routen</surname><given-names>A.</given-names></name>
<name><surname>Gillies</surname><given-names>C.</given-names></name>
<name><surname>Ekezie</surname><given-names>W.</given-names></name>
<name><surname>Welford</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>A.</given-names></name>
<name><surname>Karamchandani</surname><given-names>U.</given-names></name>
<name><surname>Simms-Williams</surname><given-names>N.</given-names></name>
<name><surname>Cassambai</surname><given-names>S.</given-names></name>
<name><surname>Ardavani</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis</article-title><source>EClinicalMedicine</source><year>2023</year><volume>55</volume><fpage>101762</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101762</pub-id><pub-id pub-id-type="pmid">36474804</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00210"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>F.</given-names></name>
<name><surname>Tomasoni</surname><given-names>D.</given-names></name>
<name><surname>Falcinella</surname><given-names>C.</given-names></name>
<name><surname>Barbanotti</surname><given-names>D.</given-names></name>
<name><surname>Castoldi</surname><given-names>R.</given-names></name>
<name><surname>Mule</surname><given-names>G.</given-names></name>
<name><surname>Augello</surname><given-names>M.</given-names></name>
<name><surname>Mondatore</surname><given-names>D.</given-names></name>
<name><surname>Allegrini</surname><given-names>M.</given-names></name>
<name><surname>Cona</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Female gender is associated with long COVID syndrome: A prospective cohort study</article-title><source>Clin. Microbiol. Infect.</source><year>2022</year><volume>28</volume><fpage>611.e9</fpage><lpage>611.e16</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2021.11.002</pub-id><pub-id pub-id-type="pmid">34763058</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00210"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bowe</surname><given-names>B.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Al-Aly</surname><given-names>Z.</given-names></name>
</person-group><article-title>Postacute sequelae of COVID-19 at 2 years</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>2347</fpage><lpage>2357</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02521-2</pub-id><pub-id pub-id-type="pmid">37605079</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00210"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mogitate</surname><given-names>M.</given-names></name>
</person-group><article-title>Differences Between Patients With Chronic Epipharyngitis With and Without Previous COVID-19 Infection</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e51543</fpage><pub-id pub-id-type="doi">10.7759/cureus.51543</pub-id><pub-id pub-id-type="pmid">38173949</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00210"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Imai</surname><given-names>K.</given-names></name>
<name><surname>Yamano</surname><given-names>T.</given-names></name>
<name><surname>Nishi</surname><given-names>S.</given-names></name>
<name><surname>Nishi</surname><given-names>R.</given-names></name>
<name><surname>Nishi</surname><given-names>T.</given-names></name>
<name><surname>Tanaka</surname><given-names>H.</given-names></name>
<name><surname>Tsunoda</surname><given-names>T.</given-names></name>
<name><surname>Yoshimoto</surname><given-names>S.</given-names></name>
<name><surname>Tanaka</surname><given-names>A.</given-names></name>
<name><surname>Hiromatsu</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Epipharyngeal Abrasive Therapy (EAT) Has Potential as a Novel Method for Long COVID Treatment</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>907</elocation-id><pub-id pub-id-type="doi">10.3390/v14050907</pub-id><pub-id pub-id-type="pmid">35632649</pub-id>
</element-citation></ref><ref id="B8-viruses-17-00210"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishi</surname><given-names>K.</given-names></name>
<name><surname>Yoshimoto</surname><given-names>S.</given-names></name>
<name><surname>Nishi</surname><given-names>S.</given-names></name>
<name><surname>Nishi</surname><given-names>T.</given-names></name>
<name><surname>Nishi</surname><given-names>R.</given-names></name>
<name><surname>Tanaka</surname><given-names>T.</given-names></name>
<name><surname>Tsunoda</surname><given-names>T.</given-names></name>
<name><surname>Imai</surname><given-names>K.</given-names></name>
<name><surname>Tanaka</surname><given-names>H.</given-names></name>
<name><surname>Hotta</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>Epipharyngeal Abrasive Therapy (EAT) Reduces the mRNA Expression of Major Proinflammatory Cytokine IL-6 in Chronic Epipharyngitis</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>9205</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23169205</pub-id><pub-id pub-id-type="pmid">36012469</pub-id>
</element-citation></ref><ref id="B9-viruses-17-00210"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishi</surname><given-names>K.</given-names></name>
<name><surname>Yoshimoto</surname><given-names>S.</given-names></name>
<name><surname>Tanaka</surname><given-names>T.</given-names></name>
<name><surname>Kimura</surname><given-names>S.</given-names></name>
<name><surname>Shinchi</surname><given-names>Y.</given-names></name>
<name><surname>Yamano</surname><given-names>T.</given-names></name>
</person-group><article-title>A Potential Novel Treatment for Chronic Cough in Long COVID Patients: Clearance of Epipharyngeal Residual SARS-CoV-2 Spike RNA by Epipharyngeal Abrasive Therapy</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e33421</fpage><pub-id pub-id-type="doi">10.7759/cureus.33421</pub-id><pub-id pub-id-type="pmid">36618501</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00210"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>Q.</given-names></name>
<name><surname>Doyle</surname><given-names>M.E.</given-names></name>
<name><surname>Liu</surname><given-names>Q.R.</given-names></name>
<name><surname>Appleton</surname><given-names>A.</given-names></name>
<name><surname>O&#x02019;Connell</surname><given-names>J.F.</given-names></name>
<name><surname>Weng</surname><given-names>N.P.</given-names></name>
<name><surname>Egan</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Long-Term Dysfunction of Taste Papillae in SARS-CoV-2</article-title><source>NEJM Evid.</source><year>2023</year><volume>2</volume><pub-id pub-id-type="doi">10.1056/EVIDoa2300046</pub-id></element-citation></ref><ref id="B11-viruses-17-00210"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheung</surname><given-names>C.C.L.</given-names></name>
<name><surname>Goh</surname><given-names>D.</given-names></name>
<name><surname>Lim</surname><given-names>X.</given-names></name>
<name><surname>Tien</surname><given-names>T.Z.</given-names></name>
<name><surname>Lim</surname><given-names>J.C.T.</given-names></name>
<name><surname>Lee</surname><given-names>J.N.</given-names></name>
<name><surname>Tan</surname><given-names>B.</given-names></name>
<name><surname>Tay</surname><given-names>Z.E.A.</given-names></name>
<name><surname>Wan</surname><given-names>W.Y.</given-names></name>
<name><surname>Chen</surname><given-names>E.X.</given-names></name>
<etal/>
</person-group><article-title>Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19</article-title><source>Gut</source><year>2022</year><volume>71</volume><fpage>e9</fpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-324280</pub-id><pub-id pub-id-type="pmid">35798364</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00210"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaebler</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Lorenzi</surname><given-names>J.C.C.</given-names></name>
<name><surname>Muecksch</surname><given-names>F.</given-names></name>
<name><surname>Finkin</surname><given-names>S.</given-names></name>
<name><surname>Tokuyama</surname><given-names>M.</given-names></name>
<name><surname>Cho</surname><given-names>A.</given-names></name>
<name><surname>Jankovic</surname><given-names>M.</given-names></name>
<name><surname>Schaefer-Babajew</surname><given-names>D.</given-names></name>
<name><surname>Oliveira</surname><given-names>T.Y.</given-names></name>
<etal/>
</person-group><article-title>Evolution of antibody immunity to SARS-CoV-2</article-title><source>Nature</source><year>2021</year><volume>591</volume><fpage>639</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03207-w</pub-id><pub-id pub-id-type="pmid">33461210</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00210"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Proal</surname><given-names>A.D.</given-names></name>
<name><surname>VanElzakker</surname><given-names>M.B.</given-names></name>
<name><surname>Aleman</surname><given-names>S.</given-names></name>
<name><surname>Bach</surname><given-names>K.</given-names></name>
<name><surname>Boribong</surname><given-names>B.P.</given-names></name>
<name><surname>Buggert</surname><given-names>M.</given-names></name>
<name><surname>Cherry</surname><given-names>S.</given-names></name>
<name><surname>Chertow</surname><given-names>D.S.</given-names></name>
<name><surname>Davies</surname><given-names>H.E.</given-names></name>
<name><surname>Dupont</surname><given-names>C.L.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)</article-title><source>Nat. Immunol.</source><year>2023</year><volume>24</volume><fpage>1616</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01601-2</pub-id><pub-id pub-id-type="pmid">37667052</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00210"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stein</surname><given-names>S.R.</given-names></name>
<name><surname>Ramelli</surname><given-names>S.C.</given-names></name>
<name><surname>Grazioli</surname><given-names>A.</given-names></name>
<name><surname>Chung</surname><given-names>J.Y.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Yinda</surname><given-names>C.K.</given-names></name>
<name><surname>Winkler</surname><given-names>C.W.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Dickey</surname><given-names>J.M.</given-names></name>
<name><surname>Ylaya</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 infection and persistence in the human body and brain at autopsy</article-title><source>Nature</source><year>2022</year><volume>612</volume><fpage>758</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05542-y</pub-id><pub-id pub-id-type="pmid">36517603</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00210"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghafari</surname><given-names>M.</given-names></name>
<name><surname>Hall</surname><given-names>M.</given-names></name>
<name><surname>Golubchik</surname><given-names>T.</given-names></name>
<name><surname>Ayoubkhani</surname><given-names>D.</given-names></name>
<name><surname>House</surname><given-names>T.</given-names></name>
<name><surname>MacIntyre-Cockett</surname><given-names>G.</given-names></name>
<name><surname>Fryer</surname><given-names>H.R.</given-names></name>
<name><surname>Thomson</surname><given-names>L.</given-names></name>
<name><surname>Nurtay</surname><given-names>A.</given-names></name>
<name><surname>Kemp</surname><given-names>S.A.</given-names></name>
<etal/>
</person-group><article-title>Prevalence of persistent SARS-CoV-2 in a large community surveillance study</article-title><source>Nature</source><year>2024</year><volume>626</volume><fpage>1094</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07029-4</pub-id><pub-id pub-id-type="pmid">38383783</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00210"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>J.</given-names></name>
<name><surname>Lucas</surname><given-names>C.</given-names></name>
<name><surname>Sundaram</surname><given-names>M.</given-names></name>
<name><surname>Israelow</surname><given-names>B.</given-names></name>
<name><surname>Wong</surname><given-names>P.</given-names></name>
<name><surname>Klein</surname><given-names>J.</given-names></name>
<name><surname>Tokuyama</surname><given-names>M.</given-names></name>
<name><surname>Lu</surname><given-names>P.</given-names></name>
<name><surname>Venkataraman</surname><given-names>A.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality</article-title><source>medRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.01.04.21249236</pub-id></element-citation></ref><ref id="B17-viruses-17-00210"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cappare</surname><given-names>P.</given-names></name>
<name><surname>D&#x02019;Ambrosio</surname><given-names>R.</given-names></name>
<name><surname>De Cunto</surname><given-names>R.</given-names></name>
<name><surname>Darvizeh</surname><given-names>A.</given-names></name>
<name><surname>Nagni</surname><given-names>M.</given-names></name>
<name><surname>Gherlone</surname><given-names>E.</given-names></name>
</person-group><article-title>The Usage of an Air Purifier Device with HEPA 14 Filter during Dental Procedures in COVID-19 Pandemic: A Randomized Clinical Trial</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>5139</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph19095139</pub-id><pub-id pub-id-type="pmid">35564533</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00210"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujimoto</surname><given-names>M.</given-names></name>
<name><surname>Katayama</surname><given-names>K.</given-names></name>
<name><surname>Nishikawa</surname><given-names>K.</given-names></name>
<name><surname>Mizoguchi</surname><given-names>S.</given-names></name>
<name><surname>Oda</surname><given-names>K.</given-names></name>
<name><surname>Hirabayashi</surname><given-names>Y.</given-names></name>
<name><surname>Suzuki</surname><given-names>Y.</given-names></name>
<name><surname>Haruki</surname><given-names>A.</given-names></name>
<name><surname>Ito</surname><given-names>T.</given-names></name>
<name><surname>Murata</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>A Kidney Transplant Recipient with Recurrent Henoch-Schonlein Purpura Nephritis Successfully Treated with Steroid Pulse Therapy and Epipharyngeal Abrasive Therapy</article-title><source>Nephron</source><year>2020</year><volume>144</volume><issue>(Suppl. S1)</issue><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1159/000511166</pub-id><pub-id pub-id-type="pmid">33221802</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00210"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahawongkajit</surname><given-names>P.</given-names></name>
<name><surname>Soonthornkes</surname><given-names>N.</given-names></name>
</person-group><article-title>Comparative effectiveness of lidocaine sprays between sitting and supine position for patients undergoing upper gastrointestinal endoscopy: A prospective randomized controlled trial</article-title><source>Surg. Endosc.</source><year>2022</year><volume>36</volume><fpage>5067</fpage><lpage>5075</lpage><pub-id pub-id-type="doi">10.1007/s00464-021-08868-2</pub-id><pub-id pub-id-type="pmid">34750705</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00210"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Expertengruppe-Long-COVID</collab>
</person-group><article-title>Long COVID&#x02014;Arzneimittel: Ma&#x000df;nahmen zur Verbesserung der Versorgung von Long COVID-Erkrankten</article-title><source>Eine Ausarbeitung der Expertengruppe Long COVID Off-Label-Use im Auftrag des Bundesministeriums f&#x000fc;r Gesundheit (BMG)</source><person-group person-group-type="editor">
<collab>BMG</collab>
<collab>B.f.G.</collab>
</person-group><publisher-name>BMG Initiative LONG COVID</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2024</year><fpage>1</fpage><lpage>27</lpage></element-citation></ref><ref id="B21-viruses-17-00210"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meek</surname><given-names>H.C.</given-names></name>
<name><surname>Stenfeldt</surname><given-names>C.</given-names></name>
<name><surname>Arzt</surname><given-names>J.</given-names></name>
</person-group><article-title>Morphological and Phenotypic Characteristics of the Bovine Nasopharyngeal Mucosa and Associated Lymphoid Tissue</article-title><source>J. Comp. Pathol.</source><year>2022</year><volume>198</volume><fpage>62</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2022.07.011</pub-id><pub-id pub-id-type="pmid">36116893</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00210"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gallo</surname><given-names>O.</given-names></name>
<name><surname>Locatello</surname><given-names>L.G.</given-names></name>
<name><surname>Mazzoni</surname><given-names>A.</given-names></name>
<name><surname>Novelli</surname><given-names>L.</given-names></name>
<name><surname>Annunziato</surname><given-names>F.</given-names></name>
</person-group><article-title>The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection</article-title><source>Mucosal Immunol.</source><year>2021</year><volume>14</volume><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1038/s41385-020-00359-2</pub-id><pub-id pub-id-type="pmid">33244161</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00210"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Freitas Santoro</surname><given-names>D.</given-names></name>
<name><surname>de Sousa</surname><given-names>L.B.</given-names></name>
<name><surname>Camara</surname><given-names>N.O.S.</given-names></name>
<name><surname>de Freitas</surname><given-names>D.</given-names></name>
<name><surname>de Oliveira</surname><given-names>L.A.</given-names></name>
</person-group><article-title>SARS-CoV-2 and Ocular Surface: From Physiology to Pathology, a Route to Understand Transmission and Disease</article-title><source>Front. Physiol.</source><year>2021</year><volume>12</volume><elocation-id>612319</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2021.612319</pub-id><pub-id pub-id-type="pmid">33643063</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00210"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>N.</given-names></name>
<name><surname>Perez</surname><given-names>P.</given-names></name>
<name><surname>Kato</surname><given-names>T.</given-names></name>
<name><surname>Mikami</surname><given-names>Y.</given-names></name>
<name><surname>Okuda</surname><given-names>K.</given-names></name>
<name><surname>Gilmore</surname><given-names>R.C.</given-names></name>
<name><surname>Conde</surname><given-names>C.D.</given-names></name>
<name><surname>Gasmi</surname><given-names>B.</given-names></name>
<name><surname>Stein</surname><given-names>S.</given-names></name>
<name><surname>Beach</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 infection of the oral cavity and saliva</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>892</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01296-8</pub-id><pub-id pub-id-type="pmid">33767405</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00210"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Q.</given-names></name>
<name><surname>Milanez-Almeida</surname><given-names>P.</given-names></name>
<name><surname>Martins</surname><given-names>A.J.</given-names></name>
<name><surname>Radtke</surname><given-names>A.J.</given-names></name>
<name><surname>Hoehn</surname><given-names>K.B.</given-names></name>
<name><surname>Oguz</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Grubbs</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children</article-title><source>Nat. Immunol.</source><year>2023</year><volume>24</volume><fpage>186</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01367-z</pub-id><pub-id pub-id-type="pmid">36536106</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00210"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jankowski</surname><given-names>R.</given-names></name>
<name><surname>Rumeau</surname><given-names>C.</given-names></name>
</person-group><article-title>Physiology of the paransal sinus ostia: Endoscopic findings</article-title><source>Eur. Ann. Otorhinolaryngol. Head Neck Dis.</source><year>2018</year><volume>135</volume><fpage>147</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.anorl.2017.12.004</pub-id><pub-id pub-id-type="pmid">29338943</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00210"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baldassarri</surname><given-names>M.</given-names></name>
<name><surname>Zguro</surname><given-names>K.</given-names></name>
<name><surname>Tomati</surname><given-names>V.</given-names></name>
<name><surname>Pastorino</surname><given-names>C.</given-names></name>
<name><surname>Fava</surname><given-names>F.</given-names></name>
<name><surname>Croci</surname><given-names>S.</given-names></name>
<name><surname>Bruttini</surname><given-names>M.</given-names></name>
<name><surname>Picchiotti</surname><given-names>N.</given-names></name>
<name><surname>Furini</surname><given-names>S.</given-names></name>
<name><surname>Pedemonte</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>4096</elocation-id><pub-id pub-id-type="doi">10.3390/cells11244096</pub-id><pub-id pub-id-type="pmid">36552859</pub-id>
</element-citation></ref><ref id="B28-viruses-17-00210"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marquez-Miranda</surname><given-names>V.</given-names></name>
<name><surname>Rojas</surname><given-names>M.</given-names></name>
<name><surname>Duarte</surname><given-names>Y.</given-names></name>
<name><surname>Diaz-Franulic</surname><given-names>I.</given-names></name>
<name><surname>Holmgren</surname><given-names>M.</given-names></name>
<name><surname>Cachau</surname><given-names>R.E.</given-names></name>
<name><surname>Gonzalez-Nilo</surname><given-names>F.D.</given-names></name>
</person-group><article-title>Analysis of SARS-CoV-2 ORF3a structure reveals chloride binding sites</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.10.22.349522</pub-id></element-citation></ref><ref id="B29-viruses-17-00210"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>D.</given-names></name>
<name><surname>Gao</surname><given-names>J.</given-names></name>
<name><surname>Zou</surname><given-names>W.</given-names></name>
<name><surname>Peng</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Ling</surname><given-names>J.</given-names></name>
<name><surname>LeGeros</surname><given-names>R.Z.</given-names></name>
</person-group><article-title>Effect of ZnCl2 on plaque growth and biofilm vitality</article-title><source>Arch. Oral Biol.</source><year>2012</year><volume>57</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.archoralbio.2011.10.001</pub-id><pub-id pub-id-type="pmid">22071420</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00210"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mogitate</surname><given-names>M.</given-names></name>
</person-group><article-title>Epipharynegal Abrasive Therapy Downregulates the Number of Epipharyngeal Abrasive CD4 Cells With Symptomatic Recovery</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e50288</fpage><pub-id pub-id-type="doi">10.7759/cureus.50288</pub-id><pub-id pub-id-type="pmid">38089949</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00210"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bao</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Chu</surname><given-names>L.T.</given-names></name>
<name><surname>Kwong</surname><given-names>H.K.</given-names></name>
<name><surname>Hartanto</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Lam</surname><given-names>M.L.</given-names></name>
<name><surname>Lam</surname><given-names>R.H.W.</given-names></name>
<name><surname>Chen</surname><given-names>T.H.</given-names></name>
</person-group><article-title>Early Committed Clockwise Cell Chirality Upregulates Adipogenic Differentiation of Mesenchymal Stem Cells</article-title><source>Adv. Biosyst.</source><year>2020</year><volume>4</volume><elocation-id>e2000161</elocation-id><pub-id pub-id-type="doi">10.1002/adbi.202000161</pub-id><pub-id pub-id-type="pmid">32864891</pub-id>
</element-citation></ref><ref id="B32-viruses-17-00210"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Korn</surname><given-names>S.M.</given-names></name>
<name><surname>Dhamotharan</surname><given-names>K.</given-names></name>
<name><surname>Jeffries</surname><given-names>C.M.</given-names></name>
<name><surname>Schlundt</surname><given-names>A.</given-names></name>
</person-group><article-title>The preference signature of the SARS-CoV-2 Nucleocapsid NTD for its 5&#x02032;-genomic RNA elements</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>3331</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-38882-y</pub-id><pub-id pub-id-type="pmid">37286558</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00210"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taneja</surname><given-names>N.</given-names></name>
<name><surname>Rathbun</surname><given-names>L.</given-names></name>
<name><surname>Hehnly</surname><given-names>H.</given-names></name>
<name><surname>Burnette</surname><given-names>D.T.</given-names></name>
</person-group><article-title>The balance between adhesion and contraction during cell division</article-title><source>Curr. Opin. Cell Biol.</source><year>2019</year><volume>56</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2018.09.001</pub-id><pub-id pub-id-type="pmid">30268802</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00210"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shadloo-Jahromi</surname><given-names>A.</given-names></name>
<name><surname>Bavi</surname><given-names>O.</given-names></name>
<name><surname>Hossein Heydari</surname><given-names>M.</given-names></name>
<name><surname>Kharati-Koopaee</surname><given-names>M.</given-names></name>
<name><surname>Avazzadeh</surname><given-names>Z.</given-names></name>
</person-group><article-title>Dynamics of respiratory droplets carrying SARS-CoV-2 virus in closed atmosphere</article-title><source>Results Phys.</source><year>2020</year><volume>19</volume><fpage>103482</fpage><pub-id pub-id-type="doi">10.1016/j.rinp.2020.103482</pub-id><pub-id pub-id-type="pmid">33101885</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00210"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gusev</surname><given-names>E.</given-names></name>
<name><surname>Sarapultsev</surname><given-names>A.</given-names></name>
<name><surname>Solomatina</surname><given-names>L.</given-names></name>
<name><surname>Chereshnev</surname><given-names>V.</given-names></name>
</person-group><article-title>SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>1716</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23031716</pub-id><pub-id pub-id-type="pmid">35163638</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00210"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farid</surname><given-names>H.</given-names></name>
<name><surname>Khan</surname><given-names>M.</given-names></name>
<name><surname>Jamal</surname><given-names>S.</given-names></name>
<name><surname>Ghafoor</surname><given-names>R.</given-names></name>
</person-group><article-title>Oral manifestations of COVID-19-A literature review</article-title><source>Rev. Med. Virol.</source><year>2022</year><volume>32</volume><fpage>e2248</fpage><pub-id pub-id-type="doi">10.1002/rmv.2248</pub-id><pub-id pub-id-type="pmid">34028129</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00210"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>France</surname><given-names>K.</given-names></name>
<name><surname>Glick</surname><given-names>M.</given-names></name>
</person-group><article-title>Long COVID and oral health care considerations</article-title><source>J. Am. Dent. Assoc.</source><year>2022</year><volume>153</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.adaj.2021.08.007</pub-id><pub-id pub-id-type="pmid">34756590</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00210"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>H.E.</given-names></name>
<name><surname>Assaf</surname><given-names>G.S.</given-names></name>
<name><surname>McCorkell</surname><given-names>L.</given-names></name>
<name><surname>Wei</surname><given-names>H.</given-names></name>
<name><surname>Low</surname><given-names>R.J.</given-names></name>
<name><surname>Re&#x02019;em</surname><given-names>Y.</given-names></name>
<name><surname>Redfield</surname><given-names>S.</given-names></name>
<name><surname>Austin</surname><given-names>J.P.</given-names></name>
<name><surname>Akrami</surname><given-names>A.</given-names></name>
</person-group><article-title>Characterizing long COVID in an international cohort: 7 months of symptoms and their impact</article-title><source>EClinicalMedicine</source><year>2021</year><volume>38</volume><fpage>101019</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101019</pub-id><pub-id pub-id-type="pmid">34308300</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00210"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grach</surname><given-names>S.L.</given-names></name>
<name><surname>Seltzer</surname><given-names>J.</given-names></name>
<name><surname>Chon</surname><given-names>T.Y.</given-names></name>
<name><surname>Ganesh</surname><given-names>R.</given-names></name>
</person-group><article-title>Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</article-title><source>Mayo Clin. Proc.</source><year>2023</year><volume>98</volume><fpage>1544</fpage><lpage>1551</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2023.07.032</pub-id><pub-id pub-id-type="pmid">37793728</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00210"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rochmawati</surname><given-names>E.</given-names></name>
<name><surname>Iskandar</surname><given-names>A.C.</given-names></name>
<name><surname>Kamilah</surname><given-names>F.</given-names></name>
</person-group><article-title>Persistent symptoms among post-COVID-19 survivors: A systematic review and meta-analysis</article-title><source>J. Clin. Nurs.</source><year>2024</year><volume>33</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/jocn.16471</pub-id><pub-id pub-id-type="pmid">36426658</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00210"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stengel</surname><given-names>A.</given-names></name>
<name><surname>Malek</surname><given-names>N.</given-names></name>
<name><surname>Zipfel</surname><given-names>S.</given-names></name>
<name><surname>Goepel</surname><given-names>S.</given-names></name>
</person-group><article-title>Long Haulers-What Is the Evidence for Post-COVID Fatigue?</article-title><source>Front. Psychiatry</source><year>2021</year><volume>12</volume><elocation-id>677934</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2021.677934</pub-id><pub-id pub-id-type="pmid">34093286</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00210"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanikawa</surname><given-names>T.</given-names></name>
<name><surname>Kiba</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Hsu</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Ishii</surname><given-names>A.</given-names></name>
<name><surname>Yokogawa</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>R.</given-names></name>
<name><surname>Inoue</surname><given-names>Y.</given-names></name>
<name><surname>Kitamura</surname><given-names>M.</given-names></name>
</person-group><article-title>Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>5405</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27175405</pub-id><pub-id pub-id-type="pmid">36080170</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00210"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leitzke</surname><given-names>M.</given-names></name>
</person-group><article-title>Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?</article-title><source>Bioelectron. Med.</source><year>2023</year><volume>9</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/s42234-023-00104-7</pub-id><pub-id pub-id-type="pmid">36650574</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00210"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Rao</surname><given-names>Z.</given-names></name>
</person-group><article-title>Structural biology of SARS-CoV-2 and implications for therapeutic development</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>685</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00630-8</pub-id><pub-id pub-id-type="pmid">34535791</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00210"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>S.H.</given-names></name>
<name><surname>Ryu</surname><given-names>C.M.</given-names></name>
<name><surname>Kim</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Bacterial persistence: Fundamentals and clinical importance</article-title><source>J. Microbiol.</source><year>2019</year><volume>57</volume><fpage>829</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1007/s12275-019-9218-0</pub-id><pub-id pub-id-type="pmid">31463787</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00210"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Justo</surname><given-names>A.F.O.</given-names></name>
<name><surname>Bueno</surname><given-names>M.S.</given-names></name>
<name><surname>Barbosa</surname><given-names>G.R.</given-names></name>
<name><surname>Perosa</surname><given-names>A.H.</given-names></name>
<name><surname>Carvalho</surname><given-names>J.M.</given-names></name>
<name><surname>Bellei</surname><given-names>N.</given-names></name>
</person-group><article-title>Comparison of viral load between saliva and nasopharyngeal swabs for SARS-CoV2: The role of days of symptoms onset on diagnosis</article-title><source>Mem. Inst. Oswaldo Cruz</source><year>2021</year><volume>116</volume><fpage>e210018</fpage><pub-id pub-id-type="doi">10.1590/0074-02760210018</pub-id><pub-id pub-id-type="pmid">33886872</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00210"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theobald</surname><given-names>S.J.</given-names></name>
<name><surname>Simonis</surname><given-names>A.</given-names></name>
<name><surname>Georgomanolis</surname><given-names>T.</given-names></name>
<name><surname>Kreer</surname><given-names>C.</given-names></name>
<name><surname>Zehner</surname><given-names>M.</given-names></name>
<name><surname>Eisfeld</surname><given-names>H.S.</given-names></name>
<name><surname>Albert</surname><given-names>M.C.</given-names></name>
<name><surname>Chhen</surname><given-names>J.</given-names></name>
<name><surname>Motameny</surname><given-names>S.</given-names></name>
<name><surname>Erger</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19</article-title><source>EMBO Mol. Med.</source><year>2021</year><volume>13</volume><fpage>e14150</fpage><pub-id pub-id-type="doi">10.15252/emmm.202114150</pub-id><pub-id pub-id-type="pmid">34133077</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00210"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giacca</surname><given-names>M.</given-names></name>
</person-group><article-title>SARS-CoV-2 infection boosts inflammation in atherosclerotic plaques</article-title><source>Nat. Cardiovasc. Res.</source><year>2023</year><volume>2</volume><fpage>966</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1038/s44161-023-00358-z</pub-id><pub-id pub-id-type="pmid">39196090</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00210"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Hong</surname><given-names>B.</given-names></name>
<name><surname>Wei</surname><given-names>P.</given-names></name>
<name><surname>Pei</surname><given-names>P.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Tong</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Luo</surname><given-names>S.Z.</given-names></name>
<name><surname>Fan</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Pathogen-host adhesion between SARS-CoV-2 spike proteins from different variants and human ACE2 studied at single-molecule and single-cell levels</article-title><source>Emerg. Microbes Infect.</source><year>2022</year><volume>11</volume><fpage>2658</fpage><lpage>2669</lpage><pub-id pub-id-type="doi">10.1080/22221751.2022.2128887</pub-id><pub-id pub-id-type="pmid">36153659</pub-id>
</element-citation></ref><ref id="B50-viruses-17-00210"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tromp</surname><given-names>J.</given-names></name>
<name><surname>Wong</surname><given-names>M.</given-names></name>
<name><surname>Ouwerkerk</surname><given-names>W.</given-names></name>
<name><surname>Wu</surname><given-names>M.-Z.</given-names></name>
<name><surname>Ren</surname><given-names>Q.-W.</given-names></name>
<name><surname>Chandramouli</surname><given-names>C.</given-names></name>
<name><surname>Teramoto</surname><given-names>K.</given-names></name>
<name><surname>Teng</surname><given-names>K.T.-H.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>To</surname><given-names>K.-K.-W.</given-names></name>
<etal/>
</person-group><article-title>The association between baseline viral load and long-term risk in patients with COVID-19 in Hong Kong: A territory-wide study</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>30644</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-65764-0</pub-id><pub-id pub-id-type="pmid">39730325</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00210"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jakel</surname><given-names>B.</given-names></name>
<name><surname>Kedor</surname><given-names>C.</given-names></name>
<name><surname>Grabowski</surname><given-names>P.</given-names></name>
<name><surname>Wittke</surname><given-names>K.</given-names></name>
<name><surname>Thiel</surname><given-names>S.</given-names></name>
<name><surname>Scherbakov</surname><given-names>N.</given-names></name>
<name><surname>Doehner</surname><given-names>W.</given-names></name>
<name><surname>Scheibenbogen</surname><given-names>C.</given-names></name>
<name><surname>Freitag</surname><given-names>H.</given-names></name>
</person-group><article-title>Hand grip strength and fatigability: Correlation with clinical parameters and diagnostic suitability in ME/CFS</article-title><source>J. Transl. Med.</source><year>2021</year><volume>19</volume><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s12967-021-02774-w</pub-id><pub-id pub-id-type="pmid">33874961</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00210"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gamage</surname><given-names>A.M.</given-names></name>
<name><surname>Tan</surname><given-names>K.S.</given-names></name>
<name><surname>Chan</surname><given-names>W.O.Y.</given-names></name>
<name><surname>Lew</surname><given-names>Z.Z.R.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Tan</surname><given-names>C.W.</given-names></name>
<name><surname>Rajagopalan</surname><given-names>D.</given-names></name>
<name><surname>Lin</surname><given-names>Q.X.X.</given-names></name>
<name><surname>Tan</surname><given-names>L.M.</given-names></name>
<name><surname>Venkatesh</surname><given-names>P.N.</given-names></name>
<etal/>
</person-group><article-title>Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection In Vitro, despite Eliciting a Prolonged Antiviral Response</article-title><source>mBio</source><year>2022</year><volume>13</volume><elocation-id>e0343621</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.03436-21</pub-id><pub-id pub-id-type="pmid">35038898</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00210"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>G.</given-names></name>
<name><surname>Priya</surname><given-names>H.</given-names></name>
<name><surname>Mishra</surname><given-names>D.</given-names></name>
<name><surname>Kumar</surname><given-names>H.</given-names></name>
<name><surname>Monga</surname><given-names>N.</given-names></name>
<name><surname>Kumari</surname><given-names>K.</given-names></name>
</person-group><article-title>Oral manifestations and dental practice recommendations during COVID-19 pandemic</article-title><source>J. Fam. Med. Prim. Care</source><year>2021</year><volume>10</volume><fpage>102</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_1605_20</pub-id><pub-id pub-id-type="pmid">34017710</pub-id>
</element-citation></ref><ref id="B54-viruses-17-00210"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1130398</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1130398</pub-id><pub-id pub-id-type="pmid">36960050</pub-id>
</element-citation></ref><ref id="B55-viruses-17-00210"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berkan</surname><given-names>O.</given-names></name>
<name><surname>Kiziloglu</surname><given-names>I.</given-names></name>
<name><surname>Keles</surname><given-names>E.</given-names></name>
<name><surname>Duman</surname><given-names>L.</given-names></name>
<name><surname>Bozkurt</surname><given-names>M.</given-names></name>
<name><surname>Adibelli</surname><given-names>Z.</given-names></name>
<name><surname>Oncel</surname><given-names>G.</given-names></name>
<name><surname>Berkan</surname><given-names>N.</given-names></name>
<name><surname>Ekemen Keles</surname><given-names>Y.</given-names></name>
<name><surname>Jones</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>Does the Thymus Index Predict COVID-19 Severity?</article-title><source>J. Comput. Assist. Tomogr.</source><year>2023</year><volume>47</volume><fpage>236</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1097/RCT.0000000000001425</pub-id><pub-id pub-id-type="pmid">36728781</pub-id>
</element-citation></ref><ref id="B56-viruses-17-00210"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>For&#x0010d;i&#x00107;</surname><given-names>D.</given-names></name>
<name><surname>Mr&#x00161;i&#x00107;</surname><given-names>K.</given-names></name>
<name><surname>Peri&#x00107;-Balja</surname><given-names>M.</given-names></name>
<name><surname>Kurtovi&#x00107;</surname><given-names>T.</given-names></name>
<name><surname>Rami&#x00107;</surname><given-names>S.</given-names></name>
<name><surname>Silovski</surname><given-names>T.</given-names></name>
<name><surname>Pedi&#x00161;i&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Milas</surname><given-names>I.</given-names></name>
<name><surname>Halassy</surname><given-names>B.</given-names></name>
</person-group><article-title>An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>958</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12090958</pub-id><pub-id pub-id-type="pmid">39339989</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00210-f001"><label>Figure 1</label><caption><p>Proposed site of action of Oronasal Drainage (OND) for Long COVID treatment. (<bold>a</bold>) Schematic depiction of the human oral and nasal cavity, where the white arrow signifies the region for epipharyngeal abrasive therapy, and the red-black dots indicate ostia as the site of action for OND. (<bold>b</bold>) Schematic representation of the human oral cavity highlights numerous ostia near the tonsilla palatina, with hidden plicae unfolding through mechanical stimulation using cotton swabs. The illustration shows an enlargement of (<bold>a</bold>), highlighted with a blue dashed outline. (<bold>c</bold>) Schematic representation of the human oral cavity illustrates the arrangement of ostia within the oropharynx. Our hypothesis posits that the opening of obstructed ostia is facilitated by biochemical stimulation using 0.5% zinc chloride (ZnCl<sub>2</sub>) solution.</p></caption><graphic xlink:href="viruses-17-00210-g001" position="float"/></fig><fig position="float" id="viruses-17-00210-f002"><label>Figure 2</label><caption><p>Oronasal Drainage (OND): Procedure for a Long COVID patient. (<bold>a</bold>) Elongated, thread-like salivary secretion observed (white arrow). (<bold>b</bold>) OND in the oral cavity targeting ostia on the right palatine gland. Adhesion between tongue secretions and the swab shown by the black arrow. (<bold>c</bold>) OND on the nasal mucosa, focusing on the epipharyngeal mucosa. Visible onset of herpes simplex virus 1 (HSV-1) reactivation on the lower lip on the fourth day of OND (black arrow).</p></caption><graphic xlink:href="viruses-17-00210-g002" position="float"/></fig><fig position="float" id="viruses-17-00210-f003"><label>Figure 3</label><caption><p>Removed nasal mucosa secretion during Oronasal Drainage (OND). (<bold>a</bold>) Stringy, transparent mucus measuring several centimeters. (<bold>b</bold>) Patient expelled long, stringy, transparent secretions through snorting (white triangle). On the fourth day of OND, a few green nasal secretions were observed (black triangle). (<bold>c</bold>) Nasal-mouth secretions. No S proteins were detected; the content, especially within brackets, remains unclear.</p></caption><graphic xlink:href="viruses-17-00210-g003" position="float"/></fig><fig position="float" id="viruses-17-00210-f004"><label>Figure 4</label><caption><p>Impact of Oronasal Drainage (OND) on Long COVID Symptom Severity. (<bold>a</bold>) Weighted symptom severity score before, during (red bar) and after OND. Black data points represent symptoms (0 to 100, left y-axis) with mean displayed. Blue data points represent exercise intolerance, identified as post-exertional malaise (PEM) (0.0 to 1.0, right y-axis) with mean displayed. (<bold>b</bold>) The data encompass the complete symptom score. A thick horizontal bar within the boxplot represents the mean of symptom (0 to 250) with error bars denoting the standard error of the mean. (<bold>c</bold>) Symptom severity for dyspnea. A thick horizontal bar within the boxplot represents the mean of symptom (0 to 8) with error bars denoting the standard error of the mean; (<bold>b</bold>,<bold>c</bold>) reflect data collected before (&#x02212;3 days), during (1&#x02013;5 days), immediately after (6&#x02013;10 days), and during follow-up (&#x0003e;10 days; <italic toggle="yes">n</italic> = 35) OND sessions.</p></caption><graphic xlink:href="viruses-17-00210-g004" position="float"/></fig><fig position="float" id="viruses-17-00210-f005"><label>Figure 5</label><caption><p>Impact of Oronasal Drainage (OND) on Long COVID skin. (<bold>a</bold>) The upper panel illustrates the patient&#x02019;s hands before OND, while the lower panel shows the patient&#x02019;s hands on the fourth day of OND. (<bold>b</bold>) The upper panel illustrates the patient&#x02019;s tongue before OND, while the lower panel shows the patient&#x02019;s tongue on the fifth day of OND.</p></caption><graphic xlink:href="viruses-17-00210-g005" position="float"/></fig></floats-group></article>